511 related articles for article (PubMed ID: 36822241)
81. A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy.
Zhang R; Tang L; Wang Y; Tian Y; Wu S; Zhou B; Dong C; Zhao B; Yang Y; Xie D; Yang L
Adv Sci (Weinh); 2023 May; 10(15):e2300116. PubMed ID: 36950751
[TBL] [Abstract][Full Text] [Related]
82. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
83. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
84. Advances in Cancer Vaccine Research.
Liu N; Xiao X; Zhang Z; Mao C; Wan M; Shen J
ACS Biomater Sci Eng; 2023 Nov; 9(11):5999-6023. PubMed ID: 37921277
[TBL] [Abstract][Full Text] [Related]
85. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
Amoozgar Z; Goldberg MS
Adv Drug Deliv Rev; 2015 Aug; 91():38-51. PubMed ID: 25280471
[TBL] [Abstract][Full Text] [Related]
86. Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy.
Chen Y; Zhi S; Ou J; Gao J; Zheng L; Huang M; Du S; Shi L; Tu Y; Cheng K
ACS Nano; 2023 Sep; 17(17):16620-16632. PubMed ID: 37606341
[TBL] [Abstract][Full Text] [Related]
87. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
88. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
89. Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective.
Wu QJ; Lv WL
IET Nanobiotechnol; 2024; 2024():5593879. PubMed ID: 38863969
[TBL] [Abstract][Full Text] [Related]
90. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine.
Gowd V; Ahmad A; Tarique M; Suhail M; Zughaibi TA; Tabrez S; Khan R
Semin Cancer Biol; 2022 Nov; 86(Pt 2):624-644. PubMed ID: 35378274
[TBL] [Abstract][Full Text] [Related]
91. Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity.
Xu Y; Ma S; Zhao J; Chen H; Si X; Huang Z; Yu Z; Song W; Tang Z; Chen X
Biomaterials; 2022 May; 284():121489. PubMed ID: 35364489
[TBL] [Abstract][Full Text] [Related]
92. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Lu Q; Qi S; Li P; Yang L; Yang S; Wang Y; Cheng Y; Song Y; Wang S; Tan F; Li N
J Mater Chem B; 2019 Apr; 7(15):2499-2511. PubMed ID: 32255127
[TBL] [Abstract][Full Text] [Related]
93. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
94. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy.
Cai T; Liu H; Zhang S; Hu J; Zhang L
J Nanobiotechnology; 2021 Nov; 19(1):389. PubMed ID: 34823541
[TBL] [Abstract][Full Text] [Related]
95. Dendritic Cell-Based In Situ Nanovaccine for Reprogramming Lipid Metabolism to Boost Tumor Immunotherapy.
Qin YT; Liu XH; An JX; Liang JL; Li CX; Jin XK; Ji P; Zhang XZ
ACS Nano; 2023 Dec; 17(24):24947-24960. PubMed ID: 38055727
[TBL] [Abstract][Full Text] [Related]
96. Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants for tumor vaccination.
Feng W; Shi W; Cui Y; Xu J; Liu S; Gao H; Zhu S; Liu Y; Zhang H
Theranostics; 2023; 13(15):5266-5289. PubMed ID: 37908730
[TBL] [Abstract][Full Text] [Related]
97. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
[TBL] [Abstract][Full Text] [Related]
98. In Situ Antigen-Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy.
Li X; Zhang Y; Wu X; Chen J; Yang M; Ma F; Shi L
Small; 2022 Aug; 18(32):e2203100. PubMed ID: 35843873
[TBL] [Abstract][Full Text] [Related]
99. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
[TBL] [Abstract][Full Text] [Related]
100. Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy.
Zhang LX; Xie XX; Liu DQ; Xu ZP; Liu RT
Biomaterials; 2018 Aug; 174():54-66. PubMed ID: 29778982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
